news & media
Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivo, Blood advances 2018
Hemophilia A is an X-linked bleeding disorder caused by mutations in the factor VIII (FVIII) gene (F8).
Targeting Antigen-Specific B Cells Using Antigen-Expressing Transduced Regulatory T Cells, J Immunol 2018
Controlling immune responses in autoimmunity and to biotherapeutics is an unmet need.
Engineered MBP-specific human Tregs ameliorate MOG-induced EAE through IL-2-triggered inhibition of effector T cells, J Autoimmun 2018
Expanded polyclonal T regulatory cells (Tregs) offer great promise for the treatment of immune-mediated diseases. Inhibition by Tregs is under the control of the T-cell receptor (TCR).
FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII, Blood 2017
Replacement therapy with factor VIII (FVIII) is used in patients with hemophilia A for treatment of bleeding episodes or for prophylaxis.
Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses, Blood 2016
Expansion of human regulatory T cells (Tregs) for clinical applications offers great promise for the treatment of undesirable immune responses in autoimmunity, transplantation, allergy, and antidrug antibody responses, including inhibitor responses in hemophilia A patients.
Oligodeoxynucleotides stabilize Helios-expressing Foxp3+ human T regulatory cells during in vitro expansion, Blood 2012
Foxp3⁺ regulatory T cells (Tregs) maintain self-tolerance and adoptive therapy, and using Foxp3⁺ Tregs has been proposed as treatment for autoimmune diseases.
Copyright © 2021 TeraImmune Inc.
704 Quince Orchard Rd. STE 160 Gaithersburg, MD 20878
Phone : 301-232-4105